-
公开(公告)号：KR1020120100214A
公开(公告)日：2012-09-12
申请号：KR1020110018962
申请日：2011-03-03
Applicant: 대한민국 (식품의약품안전처장)
Abstract: PURPOSE: A quantitative analysis of hemagglutinin of influenza vaccine is provided to quantifying the hemagglutinin of influenza vaccine without standard antigen and standard antibody. CONSTITUTION: A quantitative analysis of hemagglutinin of influenza vaccine comprises the following steps: separating a standard antigen the concentration in which hemagglutinin concentration is known by using the size exclusion chromatography; separating influenza vaccines in which the hemagglutinin concentration is not know by using the size exclusion chromatography under the same condition as the first step; calculating area of peaks which show the antigen-antibody reactions by using the result of the size exclusion chromatography of the standard antigen in the first step; calculating the area of peaks corresponding to the peaks in the third step by using the size exclusion chromatography result of the influenza vaccine; multiplying by the hemagglutinin return concentration of the standard antigen in the first step after dividing the outcome of the fourth step into the outcome of the third step; and calculating concentration correcting value which is the difference of converted value of each peak area, in which the antigen-antibody reaction is displayed based on 1 micro gram of hemagglutinin performing the size exclusion chromatography is using the standard antigen provided in the first step and performing the size exclusion chromatography by using the influenza vaccine which can checks the concentration of the hemagglutinin; and dividing the result of the fifth step by the concentration correction value of the hemagglutinin of the influenza vaccine in the sixth step.
Abstract translation: 目的：提供流感疫苗血凝素的定量分析，以量化没有标准抗原和标准抗体的流感疫苗血凝素。 构成：流感疫苗血凝素的定量分析包括以下步骤：使用尺寸排阻色谱法分离标准抗原血凝素浓度的浓度; 通过在与第一步相同的条件下使用尺寸排阻色谱法分离其中血凝素浓度不知道的流感疫苗; 通过使用第一步中标准抗原的大小排阻色谱的结果计算显示抗原 - 抗体反应的峰的面积; 通过使用流感疫苗的大小排阻色谱结果计算与第三步骤中的峰对应的峰的面积; 在将第四步骤的结果除以第三步骤的结果之后，将标准抗原的血凝素返回浓度乘以第一步骤; 并且基于进行大小排阻色谱的1微克血凝素显示出其中显示抗原 - 抗体反应的每个峰面积的转化值的差异的浓度校正值是使用第一步中提供的标准抗原，并进行 通过使用可以检查血凝素浓度的流感疫苗的大小排阻色谱法; 并且将第五步骤的结果除以流感疫苗的血细胞凝集素的浓度校正值。
-
公开(公告)号：KR1020130060835A
公开(公告)日：2013-06-10
申请号：KR1020110127108
申请日：2011-11-30
Applicant: 대한민국 (식품의약품안전처장) , 경희대학교 산학협력단 , 서울대학교산학협력단
IPC: A61K31/7048 , A61K31/70 , A61P25/28
CPC classification number: A61K31/7048 , A23L2/52 , A23L33/10 , A23L33/135 , A23V2002/00 , A61K36/185 , A61K36/42 , A61K36/47 , A61K36/48 , A61K36/725
Abstract: PURPOSE: A pharmaceutical composition containing spinosin or a spinosin-containing crude drug extract is provided to effectively improve memory and learning ability and to effectively prevent and treat cognitive disorders such as dementia and amnesia. CONSTITUTION: A composition for preventing or treating cognitive disorder contains spinosin. The composition also contains one or more extracts selected from a group consisting of Zizyphus jujuba Mill var. inermis, Zizyphus jujuba Mill var. hoonensis, Zizyphus jujuba Mill var. spinosa, Passiflora edulis flavicarpa, Cayaponia tayuya, Desmodium tortuosum, Wilbrandia ebracteata, Strophioblachia fimbricalyx, Clutia abyssinica, and Saccharopolyspora spinosa. The cognitive disorders are dementia or amnesia. A food composition for preventing or treating cognitive disorders contains spinosin. [Reference numerals] (AA) Delay time(seconds); (BB) In the middle of learning; (CC) In the middle of the present experiment; (DD) Control group 3; (EE) Control group 2; (FF) Medicine injected group 1; (GG) Medicine injected group 2; (HH) Medicine injected group 3; (II) Medicine injected group 4; (JJ) Control group 1
Abstract translation: 目的：提供含有刺糖苷或含刺糖苷的生药提取物的药物组合物，有效提高记忆力和学习能力，有效预防和治疗认知障碍，如痴呆和遗忘症。 构成：用于预防或治疗认知障碍的组合物含有刺糖苷。 该组合物还含有一种或多种提取物，选自Zizyphus jujuba Mill var。 Z hus枣 枣树，枣树 菠萝，西番莲，洋葱，Cataaponia tayuya，枸杞，Wilbrandia ebracteata，Strophioblachia fimbricalyx，黑蛤和Saccharopolyspora spinosa。 认知障碍是痴呆或遗忘症。 用于预防或治疗认知障碍的食物组合物含有刺糖苷。 （附图标记）（AA）延迟时间（秒）; （BB）在学习的中间; （CC）在本实验中期; （DD）对照组3; （EE）对照组2; （FF）药物注射组1; （GG）药物注射组2; （HH）药物注射组3; （二）药物注射组4; （JJ）对照组1
-
公开(公告)号：KR1020070013640A
公开(公告)日：2007-01-31
申请号：KR1020050068095
申请日：2005-07-26
Applicant: 대한민국 (식품의약품안전처장)
IPC: A61K36/539 , A61K36/898 , A61P29/00
CPC classification number: A61K36/539 , A61K2236/331 , Y10S514/812
Abstract: A therapeutic agent for narcotics addiction is provided to inhibit drug addiction of the narcotic anodynes, so that side effects of the narcotic anodynes are suppressed. The therapeutic agent for narcotics addiction comprises the Scutellariae radix extract and betaine as effective ingredients, and a pharmaceutically acceptable carrier, wherein the Scutellariae radix extract is prepared by extracting Scutellariae radix with hot water, and drying and pulverizing it; and the mixing ratio of Scutellariae radix extract and betaine is 4:6 to 7:3.
Abstract translation: 提供麻醉药物成瘾的治疗剂以抑制麻醉药物成瘾，从而抑制麻醉药物的副作用。 毒瘾治疗剂包括黄芩提取物和甜菜碱作为有效成分，以及药学上可接受的载体，其中黄芩提取物通过用热水提取黄芩制备，并干燥并粉碎; 黄芩提取物和甜菜碱的混合比为4：6〜7：3。
-
Patent Agency Ranking
公开(公告)号：KR1020070013639A
公开(公告)日：2007-01-31
申请号：KR1020050068094
申请日：2005-07-26
Applicant: 대한민국 (식품의약품안전처장)
IPC: A61K36/66 , A61K36/539 , A61P29/00
CPC classification number: A61K36/539 , A61K36/66 , A61K2236/331
Abstract: Anodynes with reduced drug addiction are provided to improve use safety of anodynes while they maintains pain-alleviating effects by adding natural products capable of reducing drug addiction into anodynes. The anodynes with reduced drug addiction comprises morphine or nalbuphine as an anodyne, Scutellariae radix extract, betaine, and a pharmaceutically acceptable carrier, wherein the Scutellariae radix extract is prepared by heating Scutellariae radix in water and drying it, wherein the weight ratio of morphine or nalbuphine, Scutellariae radix extract and betaine is 1: 66: 44.
Abstract translation: 提供降低药物成瘾性的痴呆症，以改善痴呆症的使用安全性，同时通过添加能够将药物成瘾减少为无效的天然产物来维持疼痛缓解作用。 具有降低药物成瘾性的痴呆症包括吗啡或纳布啡作为an ne，黄芩提取物，甜菜碱和药学上可接受的载体，其中黄芩提取物通过在水中加热黄芩并干燥而制备，其中吗啡或 纳布啡，黄芩提取物和甜菜碱为1:66:44。
-
公开(公告)号：KR101258652B1
公开(公告)日：2013-04-29
申请号：KR1020110018962
申请日：2011-03-03
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본 발명은 크기 배제 크로마토그래피 방법(size exclusion high performance liquid chromatography, SE-HPLC)을 이용하여 표준항원과 표준항체가 없어도 인플루엔자 백신의 헤마글루티닌의 정량을 가능하게 한 방법으로, 기존에 인플루엔자 백신의 헤마글루티닌을 정량하는 방법인 방사면역확산법(single radial immunodiffusion technique, SRID)보다 헤마글루티닌의 농도를 확인하는 시간이 현저하게 단축되었으면서도 정량 정확도는 더 높아진 헤마글루티닌의 정량 방법이다.
-
公开(公告)号：KR100779419B1
公开(公告)日：2007-11-30
申请号：KR1020050068094
申请日：2005-07-26
Applicant: 대한민국 (식품의약품안전처장)
IPC: A61K36/66 , A61K36/539 , A61P29/00
Abstract: 몰핀 또는 날부핀인 진통제와 황금추출물, 베타인 또는 이들의 혼합물인 중독성 경감물질의 혼합물을 유효성분으로 하고, 약제학적으로 허용되는 담체를 포함하는 중독성이 경감된 진통제에 관한 것이다. 본 발명의 중독성이 경감된 진통제는 마약성 진통제의 투여에 의하여 형성되는 약물 의존성을 경감시킬 수 있으므로, 안전하고 효과적인 통증 해소에 널리 활용될 수 있을 것이다.
몰핀, 날부핀, 마약성 진통제, 황금추출물, 베타인-
公开(公告)号：KR101360109B1
公开(公告)日：2014-02-12
申请号：KR1020110127108
申请日：2011-11-30
Applicant: 대한민국 (식품의약품안전처장) , 경희대학교 산학협력단 , 서울대학교산학협력단
IPC: A61K31/7048 , A61K31/70 , A61P25/28
CPC classification number: A61K31/7048 , A23L2/52 , A23L33/10 , A23L33/135 , A23V2002/00 , A61K36/185 , A61K36/42 , A61K36/47 , A61K36/48 , A61K36/725
Abstract: 본 발명의 스피노신 또는 스피노신 함유 생약 추출물을 포함하는 약학 조성물은 인지기능 장애 질환을 예방 및 치료하는 조성물로, 기억 및 학습 능력을 효과적으로 향상시켜 치매 및 건망증과 같은 인지기능 장애 질환을 효과적으로 치료 및 예방할 수 있다.
Abstract translation: 本发明的药物组合物，其含有刺糖苷或含刺糖多糖的草药提取物，是用于预防和治疗认知功能障碍的组合物，可有效提高记忆力和学习能力，有效治疗和预防认知功能障碍如痴呆 和健忘症。
-
公开(公告)号：KR100715939B1
公开(公告)日：2007-05-09
申请号：KR1020050068095
申请日：2005-07-26
Applicant: 대한민국 (식품의약품안전처장)
IPC: A61K36/539 , A61K36/898 , A61P29/00
Abstract: 본 발명은 황금추출물, 베타인 또는 이들의 혼합물을 유효성분으로 하고, 약제학적으로 허용되는 담체를 포함하는 마약중독 치료제에 관한 것이다. 본 발명의 마약중독 치료제는 마약성 진통제의 투여에 의하여 형성되는 약물 의존성을 효과적으로 억제할 수 있으므로, 안전하고 효과적인 마약성 진통제의 부작용 해소에 널리 활용될 수 있을 것이다.
마약중독, 황금추출물, 베타인
-
-
-
-
-
-
-
Search Results
8
records
(took 0.022 seconds)
